News | Stem Cell Therapies | May 16, 2016

Stem Cell Therapy Shows Potential for Difficult-to-Treat RA Patient Population

Late-breaker study presented at SCAI 2016

May 16, 2016 — A study using a stem cell therapy to treat challenging refractory angina (RA) patients demonstrated promising results, including improvement exercise time, reduced angina and reduced mortality. The RENEW results were presented as a late-breaking clinical trial at the 2016 Society for Cardiovascular Angiography and Interventions (SCAI) annual meeting.

RA, also known as chronic symptomatic coronary artery disease, impacts an increasing number of people. Due to inadequate blood supply from severe blockages, many experience ongoing chest pain, shortness of breath, fatigue and have limited treatment options. 

RENEW was designed to determine the effectiveness of granulocyte-colony stimulating factor (G-CSF) mobilized CD34+ stem cells (CD34+) to treat RA patients. G-CSF triggers the bone marrow to produce white blood cells and stem cells and release them into the bloodstream. CD34+ are a specific type of stem cells that have been shown to increase blood flow in pre-clinical models. 

“Clinicians are seeing more RA patients because people are living longer,” said Timothy D. Henry, M.D., MSCAI, director, division of cardiology at the Cedars-Sinai Heart Institute, Los Angeles, Calif., and the study’s co-principal investigator. “Unfortunately, despite better medical care, these people are still confronting ongoing symptoms that affect their daily lives.” 

The patients had class III or IV angina on maximally tolerated medical management, had at least seven episodes of chest pain per week, were not candidates for revascularization and whose treadmill exercise time was between three to 10 minutes. Patients were randomized into three groups: 28 to open-label standard of care (SOC), 27 to blinded placebo injections, (PL) and 57 received treatment with CD34+ cells. The researchers assessed treadmill exercise time and angina frequency at three, six and 12 months and major adverse cardiac events (MACE) for up to two years. 

Exercise time for cell-treated patients increased by more than two minutes at three months (122 seconds), six months (142 seconds) and 12 months (124 seconds). This group also experienced a 40 percent decrease (relative risk 0.57) of angina at six months when compared to the PL group. 

At two years, the CD34+ cell group saw lower rates of mortality (3.7 percent) when compared with PL (10 percent) and SOC (7.1 percent). Further, the study found higher rates of MACE after two years for SOC (68 percent) patients vs. CD34+ cell (46 percent) and PL (43 percent) patients. “Cell therapy appears to be a promising approach for these patients who have few options,” Henry said. “Our results were consistent with phase 2 results from the ACT34 trial.” 

While the investigators aim was to include 444 RA patients, final results are based on 112, because the trial was prematurely terminated by the sponsor due to financial considerations. “It is unfortunate the early termination of this study precludes a full evaluation of the efficacy of this therapy for these patients with very few options,” said Tom Povsic, M.D., FSCAI, co-principal investigator, associate professor at the Duke Clinical Research Institute (DCRI) and an interventional cardiologist at Duke University School of Medicine, Durham, N.C. “Studies like RENEW are critical to developing reliable and effective cellular therapies for heart patients, and continued funding is essential to advancing the work that this study began. We need to find a way to bring these therapies to patients as quickly and safely as possible.” 

Henry reported as co-principal investigator and Steering Committee member he received modest support from Baxter. Baxter provided the DCRI, of which Povsic is an employee, research support to conduct this study. The study was sponsored by Baxter.

For more information: www. SCAI.org/SCAI2016 

 

Related Content

Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Mississippi Surgical and Vascular Center Uses Toshiba Ultimax-i FPD to Save Patients' Limbs
News | Angiography| September 14, 2017
The southern U.S. sees some of the highest numbers of chronic medical conditions, such as peripheral artery disease...
Sponsored Content | Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
Philips Showcases Integrated Vascular Solutions at VIVA 2017
News | Peripheral Artery Disease (PAD)| September 13, 2017
Philips announced its presence at the Vascular Interventional Advances (VIVA 17) Annual Conference in Las Vegas from...
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
Overlay Init